Seelos Therapeutics Valuation
Is NXE0 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of NXE0 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate NXE0's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate NXE0's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for NXE0?
Other financial metrics that can be useful for relative valuation.
| What is NXE0's n/a Ratio? | |
|---|---|
| n/a | 0x |
| n/a | n/a |
| Market Cap | US$726.67k |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 6.8x |
| Enterprise Value/EBITDA | n/a |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does NXE0's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 0.7x | ||
93M1 MPH Health Care | 0.8x | -60.2% | €101.0m |
SPRC SciSparc | 0.3x | n/a | US$758.2k |
B8FK Biofrontera | 0.8x | n/a | €17.5m |
KOAN Resonate Blends | 0.7x | n/a | US$642.6k |
NXE0 Seelos Therapeutics | 0.4x | n/a | €726.7k |
Price-To-Sales vs Peers: NXE0 is good value based on its Price-To-Sales Ratio (0.4x) compared to the peer average (1.9x).
Price to Earnings Ratio vs Industry
How does NXE0's PE Ratio compare vs other companies in the European Pharmaceuticals Industry?
Price-To-Sales vs Industry: NXE0 is good value based on its Price-To-Sales Ratio (0.4x) compared to the European Pharmaceuticals industry average (3.7x).
Price to Sales Ratio vs Fair Ratio
What is NXE0's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 0.4x |
| Fair PS Ratio | n/a |
Price-To-Sales vs Fair Ratio: Insufficient data to calculate NXE0's Price-To-Sales Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.